Retatrutide in Type 2 Diabetes: What TRANSCEND-T2D-1 Showed

Retatrutide is Eli Lilly's investigational GIP, GLP-1, and glucagon triple receptor agonist. Most published attention has centred on its obesity program, but the compound was designed for glucose control as much as weight, and searches for retatrutide and type 2 diabetes have lacked a single primary-source answer. TRANSCEND-T2D-1 fills that gap: it is the diabetes arm of the late-stage program and the first Phase 3 retatrutide trial to report full peer-reviewed results in any indication, published in The Lancet in June 2026.^[1] This page reads the trial conservatively and keeps to what the paper reports. For the obesity Phase 3 numbers, use the TRIUMPH trial tracker; for the wider program overview, see retatrutide clinical trials.

What Is TRANSCEND-T2D-1?

TRANSCEND-T2D-1 was a 40-week, Phase 3, randomised, double-blind, placebo-controlled trial run at 48 sites across the USA, Mexico, and India. It enrolled adults with type 2 diabetes inadequately controlled by diet and exercise alone, with a baseline HbA1c between 7.0% and 9.5% and a BMI of at least 23 kg/m². Participants were randomly assigned 1:1:1:1 to once-weekly subcutaneous retatrutide at 4 mg, 9 mg, or 12 mg, or to placebo. The primary endpoint was the change in HbA1c from baseline to week 40, and the key secondary endpoint was percentage change in bodyweight over the same period. The trial is registered as NCT06354660 and is completed.^[1][4]

One design detail matters for reading the numbers: this was a monotherapy study in people relatively early in the disease (mean diabetes duration 2.5 years), not an add-on to metformin or insulin. That makes the placebo-subtracted effect a clean read of retatrutide's own glycaemic action.

HbA1c Results by Dose

Retatrutide met its primary endpoint at all three doses. For the treatment-regimen estimand, mean HbA1c fell −1.69% at 4 mg, −1.86% at 9 mg, and −1.94% at 12 mg, versus −0.81% for placebo at week 40. The estimated treatment differences versus placebo were −0.88, −1.04, and −1.12 percentage points respectively, each with p<0.0001. From a mean baseline of 7.9%, reductions of that size move mean HbA1c toward the near-normal range on the higher doses.^[1]

Weight Loss in the Diabetes Population

Bodyweight, the key secondary endpoint, also fell in a dose-dependent way: −11.5% at 4 mg, −13.9% at 9 mg, and −15.3% at 12 mg, versus −2.6% for placebo.^[1] Those numbers are substantial, but they sit below the headline figures from retatrutide's obesity studies — the Phase 2 obesity trial reported up to roughly 24% weight loss at 48 weeks, and the pivotal TRIUMPH-1 obesity readout reported still larger figures.^[3][5]

This gap is expected rather than surprising. Incretin drugs consistently produce less weight loss in type 2 diabetes than in obesity-only populations, for reasons that include physiological differences in how people with diabetes respond and the way energy balance shifts once glucose control improves. The takeaway is to compare like with like: TRANSCEND-T2D-1 is a diabetes trial, and its weight numbers should be read against other diabetes trials, not against the obesity program. The head-to-head context sits in retatrutide vs tirzepatide vs CagriSema.

Where TRANSCEND-T2D-1 Sits in the Retatrutide Program

The diabetes evidence for retatrutide did not start here. A Phase 2 diabetes trial (Rosenstock and colleagues, published in The Lancet in 2023) first showed dose-dependent HbA1c and weight reductions over 36 weeks, including an active comparator arm.^[2] TRANSCEND-T2D-1 is the Phase 3 confirmation of that signal in a larger, longer, placebo-controlled design — and, because it reached full peer-reviewed publication first, it is currently the most citable late-stage retatrutide dataset in any indication.

Running in parallel is the obesity-focused TRIUMPH Phase 3 program, tracked separately in the TRIUMPH trial tracker, plus additional diabetes and cardiovascular/kidney studies under the TRANSCEND banner. For the full late-stage map and expected regulatory timeline, see retatrutide clinical trials and the approval tracker.

Why a Triple Agonist Affects Blood Sugar

Retatrutide's glucose effect comes from its pharmacology: it activates the GLP-1, GIP, and glucagon receptors at once. The GLP-1 and GIP arms drive glucose-dependent insulin secretion — meaning they promote insulin release mainly when blood glucose is elevated, which is part of why no severe hypoglycaemia was seen in the trial. The glucagon arm, counterintuitive for a glucose-lowering drug, is thought to contribute through increased energy expenditure and hepatic effects that, in combination with the incretin arms, still net to improved glycaemic control and weight loss. The receptor-by-receptor detail lives in the GLP-1/GIP/glucagon mechanism of action guide, and the full drug profile in the retatrutide profile.

Safety and Tolerability Signals

The reported adverse-event profile was consistent with GLP-1-class molecules. The most frequent adverse events were generally mild-to-moderate gastrointestinal events — the nausea, vomiting, and diarrhoea familiar from the drug class — and the paper notes they subsided over time. Study-drug discontinuations due to adverse events were 2–5% with retatrutide versus 0% with placebo. No severe hypoglycaemia was reported. Two deaths occurred during the study, both in the retatrutide 4 mg group and reported by the investigators as unrelated to the study drug.^[1]

As in the obesity program, the gradual dose-escalation design is part of how tolerability is managed — exposure is built up in steps rather than started at the maintenance dose. The class-wide adverse-event picture, severity stratification, and how the long half-life shapes escalation are covered in the retatrutide side effects guide and the half-life page.

What This Trial Does — and Doesn't — Establish

TRANSCEND-T2D-1 establishes that, in a controlled Phase 3 setting, retatrutide monotherapy produced large, statistically decisive improvements in HbA1c and bodyweight over 40 weeks in adults with early type 2 diabetes, with a tolerability profile in line with its drug class. That is a meaningful addition to the peer-reviewed evidence base.

It does not change retatrutide's regulatory status. The compound remains investigational and unapproved for any use, and a single 40-week monotherapy trial is one input into a much larger evidence package that regulators weigh — including longer-term outcomes, cardiovascular and kidney endpoints, and add-on settings. Nothing on this page is medical advice, and the figures here describe trial observations in a study population, not outcomes any individual should expect. For where retatrutide actually stands with regulators, keep the approval tracker bookmarked.